Does ETOPOSIDE Cause Second primary malignancy? 573 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 573 reports of Second primary malignancy have been filed in association with ETOPOSIDE (Avopef). This represents 1.1% of all adverse event reports for ETOPOSIDE.
573
Reports of Second primary malignancy with ETOPOSIDE
1.1%
of all ETOPOSIDE reports
248
Deaths
105
Hospitalizations
How Dangerous Is Second primary malignancy From ETOPOSIDE?
Of the 573 reports, 248 (43.3%) resulted in death, 105 (18.3%) required hospitalization, and 54 (9.4%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ETOPOSIDE. However, 573 reports have been filed with the FAERS database.
What Other Side Effects Does ETOPOSIDE Cause?
Off label use (6,495)
Febrile neutropenia (5,966)
Disease progression (3,776)
Drug ineffective (3,687)
Neutropenia (3,641)
Thrombocytopenia (3,085)
Product use in unapproved indication (2,774)
Anaemia (2,586)
Pyrexia (2,453)
Sepsis (2,211)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
PREDNISONE (517)
OCTREOTIDE (496)
METHOTREXATE (414)
Which ETOPOSIDE Alternatives Have Lower Second primary malignancy Risk?
ETOPOSIDE vs ETORICOXIB
ETOPOSIDE vs ETRASIMOD ARGININE
ETOPOSIDE vs ETRAVIRINE
ETOPOSIDE vs EUCALYPTOL\MENTHOL\METHYL SALICYLATE\THYMOL
ETOPOSIDE vs EVEROLIMUS